INCB099280 + ipilimumab

**INCB099280 + ipilimumab** is an investigational combination therapy under clinical evaluation for select advanced solid tumors such as melanoma, colorectal carcinoma (CRC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) cancers[1][3][5][7]. - **INCB099280** is an orally administered small molecule PD-L1 (Programmed Death-Ligand 1) inhibitor, designed to block the PD-L1 protein on tumor cells and restore immune system activity against cancer[7]. - **Ipilimumab** is a monoclonal antibody checkpoint inhibitor targeting CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4), approved for advanced melanoma and under study for other tumors; it works by enhancing the activity of T cells to attack cancer cells[2][4][5]. The combination represents dual immune checkpoint blockade, aiming to synergistically stimulate anti-tumor immune responses by removing two distinct inhibitory signals—PD-L1-mediated and CTLA-4-mediated immunosuppression[5][7]. Preliminary studies focus on safety, tolerability, pharmacokinetics, and efficacy of the combination in solid tumor settings[1][3][5].

Brand names

ipilimumab

Other names

INCB099280 with ipilimumabINCB-099280 with ipilimumabINCB 099280 with ipilimumabINCB 99280 + ipilimumab